New Study Shows DCT Components Boost Diversity, But Gaps Remain for Black Participants
DCT Components, The lack of diversity in clinical trials has been a persistent issue, with racial, ethnic, and gender disparities often leaving underrepresented communities excluded from critical research. However, new data from Medable Inc. and the Tufts Center for the Study of Drug Development (CSDD) offers hope: decentralized clinical trial (DCT) components are proving to be a game-changer in improving access and representation. While the study highlights significant progress in participation among Asian, Indigenous, and female participants, it also reveals ongoing challenges in engaging Black and African American communities, underscoring the need for more tailored approaches.
The Promise of Decentralized Clinical Trials
Decentralized clinical trials leverage technology to move aspects of research out of traditional clinical settings and into patients’ homes or local communities. This approach has shown remarkable potential in addressing barriers to participation, such as geographic distance, time constraints, and lack of access to trial sites. According to the study, conducted through the PACT Consortium, DCT-enabled trials have led to notable increases in diversity.
For example, Asian participation rose by 6 percentage points, from 14.2% in traditional trials to 20.9% in DCT-enabled trials. Representation of American Indian and Alaska Native participants nearly quadrupled, increasing from 0.5% to 1.9%. Female participation also saw a significant boost, climbing from 49.0% to 55.7%, addressing a long-standing gender gap in clinical research.
Despite these gains, the study found that Black and African American participants did not experience similar improvements. Their representation in DCT-enabled trials remained largely unchanged compared to traditional trials, highlighting the need for more targeted strategies to address the unique barriers faced by this community.
The Complexity of Achieving Equity
Ken Getz, Executive Director of Tufts CSDD and a professor of research, emphasized that while DCT components are associated with improved racial and ethnic diversity, the results vary widely depending on patient preferences, disease conditions, and the specific DCT tools used. For instance, a separate study found that decentralized elements like local labs were more effective in increasing participation among Black participants, suggesting that customization is key.
“There is no one-size-fits-all solution,” Getz explained. “To truly improve diversity, we need to take a more strategic and intentional approach, tailoring DCT components to the specific needs of underrepresented groups.”
The Role of the PACT Consortium
The PACT Consortium, managed by Tufts CSDD and supported by over 30 pharmaceutical companies, tech providers, and regulatory bodies, is at the forefront of efforts to improve clinical trial diversity and efficiency. Members include industry leaders like AbbVie, Amgen, Gilead, and Pfizer, as well as the FDA and NIH. The consortium’s mission is to create a data-driven blueprint for clinical trial conduct, with a focus on enhancing patient access and representation.
Dr. Pamela Tenaerts, Chief Scientific Officer at Medable and a founding member of the PACT Consortium, highlighted the importance of evidence-based approaches. “Our first year was about building consensus and gathering data,” she said. “With nearly 70 trials analyzed so far, we plan to double that number next year to further refine our understanding of how DCT components can be optimized.”
Medable’s Impact on Clinical Trials
Medable, a global leader in clinical trial technology, has been instrumental in advancing decentralized approaches. Its software-as-a-service platform has supported over 300 decentralized and hybrid trials across 70 countries, benefiting more than one million patients and research participants. The company has achieved impressive results, including a 90% adherence rate to electronic clinical outcome assessments (eCOA) and cost reductions of up to 50%.
A Tufts CSDD study also revealed that decentralized trials can deliver significant financial returns, with Phase II and III trials generating ROI of $10 million and $39 million, respectively, for an initial investment of $500K to $1.5M. These findings underscore the economic and operational benefits of DCT approaches, in addition to their potential to improve diversity.
DCT Components DCT Components
Medable has further expanded its capabilities with the launch of Medable AI and Medable Studio, which automate the conversion of outcomes assessments into fully digital eCOAs in seconds. This innovation, now available on the Google Cloud Marketplace, enhances the scalability and accessibility of clinical trials, particularly for underrepresented communities.
Challenges and Opportunities
While DCT components have shown clear benefits, the study also highlights the complexity of achieving equitable representation. Not all decentralized tools are equally effective across demographic groups, and patient preferences play a critical role in determining participation. For example, virtual visits or home-based testing may appeal to some patients but pose logistical or technological challenges for others.
Regulatory bodies like the FDA and NIH are playing a crucial role in facilitating the adoption of decentralized trials. The FDA, in particular, has made strides in approving and regulating DCTs, which can streamline enrollment, improve access, and reduce costs. Government policies aimed at increasing trial diversity are also supporting the expansion of decentralized approaches in underrepresented regions.
The Path Forward
The findings from Medable and Tufts CSDD underscore the importance of continued innovation and customization in clinical trial design. While DCT components are a powerful tool for improving diversity, they must be deployed strategically to address the unique needs of different communities. This includes understanding and addressing barriers such as distrust of the medical system, lack of awareness about clinical trials, and socioeconomic challenges.
The PACT Consortium, in collaboration with Medable, is committed to refining its strategies and collecting more data to enhance trial inclusivity. By focusing on patient-centered approaches and leveraging cutting-edge technology, the goal is to make clinical trials more accessible and representative of the diverse populations they aim to serve.
DCT Components
